Enhanced Sensitivity to IGF-II Signaling Links Loss of Imprinting Ofigf2to Increased Cell Proliferation and Tumor Risk

Atsushi Kaneda,Chiaochun J. Wang,Raymond Cheong,Winston Timp,Patrick Onyango,Bo Wen,Christine A. Lacobuzio-Donahuel,Rolf Ohlsson,Rita Andraos,Mark A. Pearson,Alexei A. Sharov,Dan L. Longol,Minoru S. H. Ko,Andre Levchenko,Andrew P. Feinberg
DOI: https://doi.org/10.1073/pnas.0710359105
2007-01-01
Abstract:Loss of imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to abnormal activation of the normally silent maternal allele, is a common human epigenetic population variant associated with a 5-fold increased frequency of colorectal neoplasia. Here, we show first that LOI leads specifically to increased expression of proliferation-related genes in mouse intestinal crypts. Surprisingly, LOI(+) mice also have enhanced sensitivity to IGF-II signaling, not simply increased IGF-II levels, becausein vivoblockade with NVP-AEW541, a specific inhibitor of the IGF-II signaling receptor, showed reduction of proliferation-related gene expression to levels half that seen in LOI(−) mice. Signal transduction assays in microfluidic chips confirmed this enhanced sensitivity with marked augmentation of Akt/PKB signaling in LOI(+) cells at low doses of IGF-II, which was reduced in the presence of the inhibitor to levels below those found in LOI(−) cells, and was associated with increased expression of the IGF1 and insulin receptor genes. We exploited this increased IGF-II sensitivity to develop anin vivochemopreventive strategy using the azoxymethane (AOM) mutagenesis model. LOI(+) mice treated with AOM showed a 60% increase in premalignant aberrant crypt foci (ACF) formation over LOI(−) mice.In vivoIGF-II blockade with NVP-AEW541 abrogated this effect, reducing ACF to a level 30% lower even than found in exposed LOI(−) mice. Thus, LOI increases cancer risk in a counterintuitive way, by increasing the sensitivity of the IGF-II signaling pathway itself, providing a previously undescribed epigenetic chemoprevention strategy in which cells with LOI are “IGF-II addicted” and undergo reduced tumorigenesis in the colon upon IGF-II pathway blockade.
What problem does this paper attempt to address?